S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Is This The End of Capitalism? (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
The Next Big Crisis Is Here (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Is This The End of Capitalism? (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
The Next Big Crisis Is Here (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Is This The End of Capitalism? (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
The Next Big Crisis Is Here (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Is This The End of Capitalism? (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
The Next Big Crisis Is Here (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
NASDAQ:JNCE

Jounce Therapeutics - JNCE Stock Forecast, Price & News

$1.13
-0.06 (-5.04%)
(As of 01/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.12
$1.22
50-Day Range
$0.64
$1.29
52-Week Range
$0.58
$8.80
Volume
262,512 shs
Average Volume
963,137 shs
Market Capitalization
$58.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.20

Jounce Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
625.7% Upside
$8.20 Price Target
Short Interest
Healthy
3.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
1.15mentions of Jounce Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$41,929 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.98) to ($2.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.66 out of 5 stars

Medical Sector

92nd out of 1,055 stocks

Biological Products, Except Diagnostic Industry

15th out of 170 stocks


JNCE stock logo

About Jounce Therapeutics (NASDAQ:JNCE) Stock

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

Receive JNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JNCE Stock News Headlines

Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
JNCE.O - | Stock Price & Latest News | Reuters
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Jounce Therapeutics
See More Headlines
Receive JNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JNCE Company Calendar

Last Earnings
11/10/2022
Today
1/30/2023
Next Earnings (Estimated)
3/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:JNCE
Fax
N/A
Employees
137
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.20
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+625.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-90,870,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$26.91 million
Book Value
$4.37 per share

Miscellaneous

Free Float
48,117,000
Market Cap
$58.41 million
Optionable
Optionable
Beta
0.88

Key Executives

  • Dr. Richard Murray Ph.D. (Age 64)
    Pres, CEO & Director
    Comp: $887.4k
  • Mr. Hugh M. Cole (Age 58)
    Chief Operating Officer
    Comp: $607.44k
  • Dr. Elizabeth G. Trehu M.D. (Age 63)
    Chief Medical Officer
    Comp: $639.6k
  • Dr. James Patrick Allison Ph.D.
    Founder
  • Dr. Thomas F. Gajewski M.D.
    Ph.D., Founder
  • Dr. Robert D. Schreiber Ph.D.
    Founder
  • Dr. Drew Mark Pardoll M.D.
    Ph.D., Founder
  • Dr. Padmanee Sharma M.D.
    Ph.D., Founder
  • Dr. Louis M. Weiner M.D. (Age 71)
    Founder
  • Ms. Kimberlee Cobleigh Drapkin CPA (Age 55)
    CPA, CFO & Treasurer













JNCE Stock - Frequently Asked Questions

Should I buy or sell Jounce Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" JNCE shares.
View JNCE analyst ratings
or view top-rated stocks.

What is Jounce Therapeutics' stock price forecast for 2023?

6 equities research analysts have issued 1-year price targets for Jounce Therapeutics' stock. Their JNCE share price forecasts range from $3.00 to $17.00. On average, they anticipate the company's stock price to reach $8.20 in the next year. This suggests a possible upside of 625.7% from the stock's current price.
View analysts price targets for JNCE
or view top-rated stocks among Wall Street analysts.

How have JNCE shares performed in 2023?

Jounce Therapeutics' stock was trading at $1.11 at the beginning of 2023. Since then, JNCE stock has increased by 1.8% and is now trading at $1.13.
View the best growth stocks for 2023 here
.

Are investors shorting Jounce Therapeutics?

Jounce Therapeutics saw a drop in short interest in the month of January. As of January 15th, there was short interest totaling 1,580,000 shares, a drop of 46.3% from the December 31st total of 2,940,000 shares. Based on an average trading volume of 1,550,000 shares, the short-interest ratio is presently 1.0 days. Approximately 4.0% of the company's shares are short sold.
View Jounce Therapeutics' Short Interest
.

When is Jounce Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 1st 2023.
View our JNCE earnings forecast
.

How were Jounce Therapeutics' earnings last quarter?

Jounce Therapeutics, Inc. (NASDAQ:JNCE) issued its quarterly earnings data on Thursday, November, 10th. The company reported ($0.60) EPS for the quarter, beating analysts' consensus estimates of ($0.64) by $0.04.

What is Richard Murray Ph.D's approval rating as Jounce Therapeutics' CEO?

45 employees have rated Jounce Therapeutics Chief Executive Officer Richard Murray Ph.D on Glassdoor.com. Richard Murray Ph.D has an approval rating of 97% among the company's employees. This puts Richard Murray Ph.D in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jounce Therapeutics own?
When did Jounce Therapeutics IPO?

(JNCE) raised $76 million in an IPO on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

What is Jounce Therapeutics' stock symbol?

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

Who are Jounce Therapeutics' major shareholders?

Jounce Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (1.01%), Moloney Securities Asset Management LLC (0.93%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin, Richard /Ca/ Murray, Rock Ventures Ii LP Third and Rock Ventures Iii LP Third.
View institutional ownership trends
.

How do I buy shares of Jounce Therapeutics?

Shares of JNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jounce Therapeutics' stock price today?

One share of JNCE stock can currently be purchased for approximately $1.13.

How much money does Jounce Therapeutics make?

Jounce Therapeutics (NASDAQ:JNCE) has a market capitalization of $58.41 million and generates $26.91 million in revenue each year. The company earns $-90,870,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis.

How many employees does Jounce Therapeutics have?

The company employs 137 workers across the globe.

How can I contact Jounce Therapeutics?

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.jouncetx.com. The company can be reached via phone at (857) 259-3840 or via email at mdeon@jouncetx.com.

This page (NASDAQ:JNCE) was last updated on 1/31/2023 by MarketBeat.com Staff